(Hypertension. 2001;38:183.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP
From the University of Virginia Health System, Charlottesville.
Reprint requests to Helmy M. Siragy, MD, Department of Medicine, University of Virginia Health Sciences Center, 1300 Jefferson Park Ave, Charlottesville, VA 22908. E-mail hms7a{at}virginia.edu
Abstract—— Angiotensin (Ang) receptor blockers (ARBs) increase bradykinin (BK) by antagonizing Ang II at its type 1 (AT1) receptors and diverting Ang II to its counterregulatory type 2 (AT2) receptors. Because the effect of ARBs on BK is constrained by the short half-life of BK and because ACE inhibitors block the degradation of BK, this study was designed to test the hypothesis that an ACE inhibitor can potentiate ARB-induced increases in renal interstitial fluid (RIF) BK levels. We used a microdialysis technique to recover BK and cGMP in vivo from the RIF of sodium-depleted, conscious Sprague-Dawley rats infused for 60 minutes with the AT1 receptor blocker valsartan (0.17 mg/kg per minute), with the active metabolite of the ACE inhibitor benazepril (benazeprilate, 0.05 mg/kg per minute), or with the specific AT2 receptor blocker PD 123,319 (50 µg/kg per minute) alone or combined. Each animal served as its own control. RIF BK and cGMP levels increased significantly over 1 hour in response to valsartan, benazeprilate, or both but not to a vehicle control (P<0.01). The combined benazeprilate-valsartan effect was greater than the sum of their individual effects, suggesting potentiation rather than addition, and was abolished by PD 123,319. We demonstrate for the first time that an ACE inhibitor (benazepril) and an ARB (valsartan) potentiate each other, and we postulate that such combinations may be beneficial in clinical states marked by Ang II elevation, such as chronic heart failure, postinfarction left ventricular dysfunction, and hypertension.
Key Words: angiotensin-converting enzyme inhibitors • receptors, angiotensin II • bradykinin • rats • cyclic GMP
This article has been cited by other articles:
 |
|
 |
|
  D. C. Isbell, S. Voros, Z. Yang, J. M. DiMaria, S. S. Berr, B. A. French, F. H. Epstein, S. P. Bishop, H. Wang, R. J. Roy, et al. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3372 - H3378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K Irons and A. Kumar Valsartan-Induced Angioedema Ann. Pharmacother., July 1, 2003; 37(7): 1024 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Blann, S. Nadar, and G. Y.H. Lip Pharmacological Modulation of Platelet Function in Hypertension Hypertension, July 1, 2003; 42(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, H. Yamakawa, C. Bregonzio, J. A. Terron, A. Falcon-Neri, and J. M. Saavedra Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT1 Antagonist Stroke, September 1, 2002; 33(9): 2297 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Sica Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 66 - 71. [Abstract] [PDF]
|
|